Sofosbuvir-velpatasvir-voxilaprevir provides salvage therapy for NS5A failures
Mark Fuerst
Advertisement
Articles by Mark Fuerst
Despite the availability of new, highly successful direct-acting antiviral (DAA) regimens, more than one third of chronic hepatitis C (HCV) patients are denied access to treatment by their insurance provider, according to a new study.
Advertisement
Latest Updated Articles
- More than one-third of hepatitis C patients denied insurance coverage
Published: July 3rd 2018 | Updated:
- Direct-acting antiviral combination retreats chronic hepatitis C failures
Published: July 3rd 2018 | Updated:
Advertisement
Advertisement
Trending on Medical Economics
1
‘Physician associate’ title gains momentum across state legislatures
2
Five top takeaways from the 2025 Concierge Medicine Forum
3
How remote patient monitoring improves care while reducing costs
4
Light and sound therapy dimming Alzheimer’s decline; AI coach matches humans in diabetes prevention; stillbirths more common than previously thought – Morning Medical Update
5
